Vis enkel innførsel

dc.contributor.authorJohnsen, Eriken_US
dc.contributor.authorFathian, Farivaren_US
dc.contributor.authorKroken, Rune Aen_US
dc.contributor.authorSteen, Vidar Men_US
dc.contributor.authorJørgensen, Hugo Aen_US
dc.contributor.authorGjestad, Rolfen_US
dc.contributor.authorLøberg, Else-Marieen_US
dc.date.accessioned2016-04-28T09:50:32Z
dc.date.available2016-04-28T09:50:32Z
dc.date.issued2016-03-14
dc.PublishedBMC Psychiatry. 2016 Mar 14;16(1):60eng
dc.identifier.urihttps://hdl.handle.net/1956/11957
dc.description.abstractBackground Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis. Methods A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status. Results There was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels. Conclusions The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis. Trial registration ClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009en_US
dc.language.isoengeng
dc.publisherBioMed Centraleng
dc.rightsAttribution CC BY 4.0eng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.subjectSchizophreniaeng
dc.subjectCognitioneng
dc.subjectInflammationeng
dc.subjectCRPeng
dc.titleThe serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosisen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2016-03-15T07:08:30Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright Johnsen et al. 2016
dc.identifier.doihttps://doi.org/10.1186/s12888-016-0769-x
dc.subject.nsiVDP::Medisinske Fag: 700en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY 4.0
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY 4.0